Cognizant will provide AI-driven solutions
to enhance customer service, employee engagement, and business
value
TEANECK,
N.J., Jan. 30, 2025 /PRNewswire/ --
Cognizant (NASDAQ: CTSH) has announced an expansion of its
longstanding relationship with biopharmaceutical leader Gilead
Sciences (NASDAQ: GILD) that aims to unlock even greater value
for Gilead as it advances innovations to prevent and treat
life-threatening diseases. The expanded agreement aims to deliver
greater cost leadership and productivity enhancement for Gilead
while seeking to extract greater value from the existing
relationship. Leveraging machine learning and generative AI within
an agentic framework, the work addresses multiple use cases across
customer service, employee interactions, and business value
management. Gilead is expected to enhance its efficiency through
leveraging Cognizant's expertise in AI and advanced technology
applications. By deploying these cutting-edge solutions across the
value chain, Cognizant aims to help Gilead achieve significant
benefits through a newly optimized financial framework.
Over the last decade, Cognizant has helped support Gilead's
global IT infrastructure, platforms, applications and advanced
analytics, and leads initiatives designed to accelerate its digital
transformation. Today's announcement builds on a
collaboration aimed at creating capacity to allow Gilead to
continue its focus and mission, aimed at discovering and delivering
critical medicines for cancer, HIV and other diseases.
"Cognizant continues to provide critical expertise as we advance
our technology journey," said Joydeep
Ganguly, SVP & Head – Corporate Operations and Interim
CIO at Gilead. "The expansion of this partnership is pivotal in
accelerating our capabilities roadmap while driving a new level of
cost leadership across our technology programs. This collaboration
aims to bring innovative changes to Gilead's business, exploring
new possibilities and enhancing our operations in novel ways."
Expanding on the company's partnership, Cognizant intends to
leverage its Neuro AI generative AI platform to assist Gilead in
accelerating value creation, enhancing IT and business processes,
and improving operational efficiencies. This initiative aims to
provide significant cost savings, which can be reinvested into
Gilead's core life sciences business. As part of this expanded
agreement, Cognizant also intends to transform the user experience
of IT services with custom-built Gen AI solutions that allow Gilead
to benefit from greater efficiency and user experience.
"We're proud of our longstanding relationship with Gilead, a
leader in leveraging advanced technologies, and are excited about
expanding our partnership in a new dimension with the company to
deliver transformative treatments globally," said Surya Gummadi,
EVP and President, Cognizant Americas. "Our teams will work
together to transform user engagement, and boost productivity and
cost savings for Gilead to focus on the critical work they do
around preventing and treating life-threatening illnesses."
"This agreement allows us to provide end-to-end Cognizant
capabilities through our life sciences domain expertise to provide
value acceleration to Gilead," said Mohammad Haque, SVP, Global Large Deals Lead and
Business Unit Head, Life Sciences, Cognizant. "Utilizing
Cognizant's premier managed services frameworks and tools we intend
to enhance operational efficiencies with leading-edge
automation."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers
modern businesses. We help our clients modernize technology,
reimagine processes and transform experiences so they can stay
ahead in our fast-changing world. Together, we're improving
everyday life. See how at www.cognizant.com or @cognizant.
About Gilead
Gilead Sciences, Inc. is a
biopharmaceutical company that has pursued and achieved
breakthroughs in medicine for more than three decades, with the
goal of creating a healthier world for all people. The company is
committed to advancing innovative medicines to prevent and treat
life-threatening diseases, including HIV, viral hepatitis,
COVID-19, and cancer. Gilead operates in more than 35 countries
worldwide, with headquarters in Foster
City, California.
For more information, contact:
Natalie
Steffen
Natalie.Steffen@cognizant.com
300 Frank W. Burr Blvd. Suite 36, 6th Floor
Teaneck, NJ 07666 USA
+1 201 801 0233 Cognizant.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cognizant-and-gilead-expand-partnership-to-drive-greater-value-through-advanced-technology-applications-302363834.html
SOURCE Cognizant Technology Solutions Corporation
